These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16704196)

  • 1. Effects of cell-permeating peptide binding on the distribution of 125I-labeled Fab fragment in rats.
    Kameyama S; Horie M; Kikuchi T; Omura T; Takeuchi T; Nakase I; Sugiura Y; Futaki S
    Bioconjug Chem; 2006; 17(3):597-602. PubMed ID: 16704196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of immunoglobulin Fab fragment conjugated with HIV-1 REV peptide following intravenous administration in rats.
    Kameyama S; Okada R; Kikuchi T; Omura T; Nakase I; Takeuchi T; Sugiura Y; Futaki S
    Mol Pharm; 2006; 3(2):174-80. PubMed ID: 16579646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and evaluation of [188Re]organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levels.
    Uehara T; Koike M; Nakata H; Hanaoka H; Iida Y; Hashimoto K; Akizawa H; Endo K; Arano Y
    Bioconjug Chem; 2007; 18(1):190-8. PubMed ID: 17226973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acid wash in determining cellular uptake of Fab/cell-permeating peptide conjugates.
    Kameyama S; Horie M; Kikuchi T; Omura T; Tadokoro A; Takeuchi T; Nakase I; Sugiura Y; Futaki S
    Biopolymers; 2007; 88(2):98-107. PubMed ID: 17252560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination.
    Wilbur DS; Chyan MK; Hamlin DK; Vessella RL; Wedge TJ; Hawthorne MF
    Bioconjug Chem; 2007; 18(4):1226-40. PubMed ID: 17583925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor cell retention of antibody Fab fragments is enhanced by an attached HIV TAT protein-derived peptide.
    Anderson DC; Nichols E; Manger R; Woodle D; Barry M; Fritzberg AR
    Biochem Biophys Res Commun; 1993 Jul; 194(2):876-84. PubMed ID: 8343170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels.
    Arano Y; Fujioka Y; Akizawa H; Ono M; Uehara T; Wakisaka K; Nakayama M; Sakahara H; Konishi J; Saji H
    Cancer Res; 1999 Jan; 59(1):128-34. PubMed ID: 9892197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide.
    Du J; Wang H; Zhong C; Peng B; Zhang M; Li B; Hou S; Guo Y; Ding J
    Mol Immunol; 2008 May; 45(10):2861-8. PubMed ID: 18346788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of an anti-cholera toxin antibody Fab in complex with an epitope-derived D-peptide: a case of polyspecific recognition.
    Scheerer P; Kramer A; Otte L; Seifert M; Wessner H; Scholz C; Krauss N; Schneider-Mergener J; Höhne W
    J Mol Recognit; 2007; 20(4):263-74. PubMed ID: 17712773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal brush border enzyme-cleavable linkages for low renal radioactivity levels of radiolabeled antibody fragments.
    Akizawa H; Imajima M; Hanaoka H; Uehara T; Satake S; Arano Y
    Bioconjug Chem; 2013 Feb; 24(2):291-9. PubMed ID: 23330714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro system to estimate renal brush border enzyme-mediated cleavage of Peptide linkages for designing radiolabeled antibody fragments of low renal radioactivity levels.
    Fujioka Y; Satake S; Uehara T; Mukai T; Akizawa H; Ogawa K; Saji H; Endo K; Arano Y
    Bioconjug Chem; 2005; 16(6):1610-6. PubMed ID: 16287261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of KAI-9803, a novel δ-protein kinase C inhibitor, after intravenous administration to rats.
    Miyaji Y; Walter S; Chen L; Kurihara A; Ishizuka T; Saito M; Kawai K; Okazaki O
    Drug Metab Dispos; 2011 Oct; 39(10):1946-53. PubMed ID: 21712433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isotope-edited NMR studies of Fab'-peptide complexes.
    Tsang P; Fieser TM; Ostresh JM; Lerner RA; Wright PE
    Pept Res; 1988; 1(2):87-92. PubMed ID: 2980784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The structure of the anti-c-myc antibody 9E10 Fab fragment/epitope peptide complex reveals a novel binding mode dominated by the heavy chain hypervariable loops.
    Krauss N; Wessner H; Welfle K; Welfle H; Scholz C; Seifert M; Zubow K; Aÿ J; Hahn M; Scheerer P; Skerra A; Höhne W
    Proteins; 2008 Nov; 73(3):552-65. PubMed ID: 18473392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of specific antibody Fab fragments on desipramine pharmacokinetics in the rat in vivo and in the isolated, perfused liver.
    Keyler DE; Le Couteur DG; Pond SM; St Peter JV; Pentel PR
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1117-23. PubMed ID: 7891324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.
    Neumann F; Sturm C; Hülsmeyer M; Dauth N; Guillaume P; Luescher IF; Pfreundschuh M; Held G
    Immunol Lett; 2009 Aug; 125(2):86-92. PubMed ID: 19524620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The world of beta- and gamma-peptides comprised of homologated proteinogenic amino acids and other components.
    Seebach D; Beck AK; Bierbaum DJ
    Chem Biodivers; 2004 Aug; 1(8):1111-239. PubMed ID: 17191902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal metabolism of 3'-iodohippuryl N(epsilon)-maleoyl-L-lysine (HML)-conjugated Fab fragments.
    Fujioka Y; Arano Y; Ono M; Uehara T; Ogawa K; Namba S; Saga T; Nakamoto Y; Mukai T; Konishi J; Saji H
    Bioconjug Chem; 2001; 12(2):178-85. PubMed ID: 11312678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering.
    Humphreys DP; Heywood SP; Henry A; Ait-Lhadj L; Antoniw P; Palframan R; Greenslade KJ; Carrington B; Reeks DG; Bowering LC; West S; Brand HA
    Protein Eng Des Sel; 2007 May; 20(5):227-34. PubMed ID: 17452434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides.
    Duchardt F; Fotin-Mleczek M; Schwarz H; Fischer R; Brock R
    Traffic; 2007 Jul; 8(7):848-66. PubMed ID: 17587406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.